ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
11/06/2025
Voltar para busca
Dado oficial do USPTO
UNIQURE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
UNIQURE
ST13
US500000085907857Classe
1, 5, 42, 44
Pedido
85907857
Registro
4710280
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
46
Atualização mais recente
12/06/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 42, 44
Data de depósito
18/04/2013
Data de registro
31/03/2015
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
27/01/2025
Última transação
12/06/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
800
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Código do desenho
4
Tipo de titular
26
Localização do titular
AMSTERDAM, NL
Examinador
LEVINE, HOWARD
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
UNIQURE BIOPHARMA B.V.
uniQure IP B.V.
Representantes
Julianne Abelman ABELMAN LAW PLLC
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Viral assaysviral reagentsviral preparationsgene therapy assaysgene therapy reagentsgene therapy preparationsnucleic acid delivery assaysnucleic acid delivery reagentsnucleic acid delivery preparationsviral vectorsnon-viral vectorsgene therapy vectorsnucleic acid delivery vectorscells transformed by viral vectorsnon-viral vectorsgene therapy vectors and nucleic acid delivery vectorsall for non-medical research purposes
Classe 5
Viral medicinesgene therapy medicinesnucleic acid delivery medicinesviral vectorsnon-viral vectorsgene therapy vectorsnucleic acid delivery vectorscells transformed by viral vectorsnon-viral vectorsgene therapy vectors and nucleic acid delivery vectors for medical purposes all for medical treatment of metabolic disordersocular disordersdiseases of the nervous systemblood disordersliver disordersmuscular disordersmuscular skeletal disorderscancersinfectious diseasesfungal diseasesdiseases caused by parasitesdiseases affecting the immune systeminflammatory and auto-immune diseasesvascular disordersbone diseasesinherited disordersgenetic disorderssingle gene disorders and cancers; pharmaceutical preparations and substances for the treatment of metabolic disordersocular disordersdiseases of the nervous systemblood disordersliver disordersmuscular disordersmuscular skeletal disorderscancersinfectious diseasesfungal diseasesdiseases caused by parasitesdiseases affecting the immune systeminflammatory and auto-immune diseasesvascular disordersbone diseasesinherited disordersgenetic disorderssingle gene disorders and cancers; biological preparations for use in medical and clinical gene therapynucleic acid-based therapy and cell therapyall for the treatment of metabolic disordersocular disordersdiseases of the nervous systemblood disordersliver disordersmuscular disordersmuscular skeletal disorderscancersinfectious diseasesfungal diseasesdiseases caused by parasitesdiseases affecting the immune systeminflammatory and auto-immune diseasesvascular disordersbone diseasesinherited disordersgenetic disorderssingle gene disorders and cancers; clinical medical reagents for use in nucleic acid-based therapygene therapycell therapygene diagnosis and gene testing in the treatment of metabolic disordersocular disordersdiseases of the nervous systemblood disordersliver disordersmuscular disordersmuscular skeletal disorderscancersinfectious diseasesfungal diseasesdiseases caused by parasitesdiseases affecting the immune systeminflammatory and auto-immune diseasesvascular disordersbone diseasesinherited disordersgenetic disorderssingle gene disorders and cancers; pharmaceutical preparationsvaccinesprophylaxis medicines and other pharmaceutical preparations all for use in nucleic acid-based therapygene therapy and cell therapy in the treatment of metabolic disordersocular disordersdiseases of the nervous systemblood disordersliver disordersmuscular disordersmuscular skeletal disorderscancersinfectious diseasesfungal diseasesdiseases caused by parasitesdiseases affecting the immune systeminflammatory and auto-immune diseasesvascular disordersbone diseasesinherited disordersgenetic disorderssingle gene disorders and cancers
Classe 42
Researchproduct development and consultancy in the field of biotechnologybiologicspharmaceuticsmedical sciencechemistry and biochemistry
Classe 44
Gene and nucleic acid deliverygene and nucleic acid transfergene and nucleic acid regulation and gene and nucleic acid modulation for the treatment of metabolic disordersocular disordersdiseases of the nervous systemblood disordersliver disordersmuscular disordersmuscular skeletal disorderscancersinfectious diseasesinflammatory and auto-immune diseasesvascular disordersinherited disordersgenetic disorders and single gene disorders
Publicações
Histórico de despachos e eventos da marca no USPTO.
46 publicações encontradas
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
04/06/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/06/2025
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
04/06/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/06/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/06/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
04/06/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
04/06/2025
NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
27/01/2025
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
27/01/2025
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
27/01/2025
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
27/01/2025
E89R
TEAS SECTION 8 & 9 RECEIVED
04/10/2024
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
31/03/2024
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
01/04/2021
C15P
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
01/04/2021
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
10/11/2020
E815
TEAS SECTION 8 & 15 RECEIVED
17/09/2020
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
31/03/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
31/03/2015
DP1B
1(B) BASIS DELETED; PROCEED TO REGISTRATION
18/11/2014
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
18/11/2014
IUCN
NOTICE OF ALLOWANCE CANCELLED
29/10/2014
D1BR
TEAS DELETE 1(B) BASIS RECEIVED
29/10/2014
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
28/10/2014
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/09/2014
PUBO
PUBLISHED FOR OPPOSITION
02/09/2014
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
13/08/2014
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
28/07/2014
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
28/07/2014
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
24/07/2014
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
24/07/2014
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
24/07/2014
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
22/02/2014
GNFR
FINAL REFUSAL E-MAILED
22/02/2014
CNFR
FINAL REFUSAL WRITTEN
22/02/2014
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
31/01/2014
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
31/01/2014
ALIE
ASSIGNED TO LIE
26/01/2014
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
16/01/2014
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
05/08/2013
GNRT
NON-FINAL ACTION E-MAILED
05/08/2013
CNRT
NON-FINAL ACTION WRITTEN
05/08/2013
DOCK
ASSIGNED TO EXAMINER
05/08/2013
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
25/04/2013
NWAP
NEW APPLICATION ENTERED
22/04/2013
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace UNIQURE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.